Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers.

Animals Antibodies, Bispecific / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Cell Line, Tumor Drug Synergism Humans Immune Checkpoint Inhibitors / therapeutic use Immunotherapy / methods Manganese / therapeutic use Mice, Inbred BALB C Neoplasms / immunology Transforming Growth Factor beta / antagonists & inhibitors
Bispecific antibody Cancer immunotherapy Manganese PD-L1 TGF-β The tumor microenvironment cGAS-STING

Journal

Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937

Informations de publication

Date de publication:
15 09 2021
Historique:
received: 22 06 2021
accepted: 30 08 2021
entrez: 16 9 2021
pubmed: 17 9 2021
medline: 23 11 2021
Statut: epublish

Résumé

Our previous work showed that the anti-TGF-β/PD-L1 bispecific antibody YM101 effectively overcame anti-PD-L1 resistance in immune-excluded tumor models. However, in immune-desert models, the efficacy of YM101 was limited. Bivalent manganese (Mn The effect of Mn Mn Combining Mn

Sections du résumé

BACKGROUND
Our previous work showed that the anti-TGF-β/PD-L1 bispecific antibody YM101 effectively overcame anti-PD-L1 resistance in immune-excluded tumor models. However, in immune-desert models, the efficacy of YM101 was limited. Bivalent manganese (Mn
METHODS
The effect of Mn
RESULTS
Mn
CONCLUSION
Combining Mn

Identifiants

DOI: 10.1186/s13045-021-01155-6 PMID: 34526097 PMC: PMC8442312
pubmed: 34526097
doi: 10.1186/s13045-021-01155-6
pii: 10.1186/s13045-021-01155-6
pmc: PMC8442312
doi:

Substances chimiques

Antibodies, Bispecific 0
Antineoplastic Agents, Immunological 0
Immune Checkpoint Inhibitors 0
Transforming Growth Factor beta 0
Manganese 42Z2K6ZL8P

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

146

Informations de copyright

© 2021. The Author(s).

Références

Cell Res. 2020 Nov;30(11):966-979
pubmed: 32839553
ACS Nano. 2020 Apr 28;14(4):3927-3940
pubmed: 32298077
J Hematol Oncol. 2019 Oct 26;12(1):110
pubmed: 31655607
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Nature. 2018 Dec;564(7736):439-443
pubmed: 30405246
Mol Aspects Med. 2005 Aug-Oct;26(4-5):353-62
pubmed: 16099026
Onco Targets Ther. 2019 Nov 11;12:9527-9538
pubmed: 31807028
J Hematol Oncol. 2020 Mar 28;13(1):25
pubmed: 32222150
J Immunother Cancer. 2018 Jun 4;6(1):47
pubmed: 29866156
Am J Dis Child. 1989 Jul;143(7):823-7
pubmed: 2741855
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Bioinformatics. 2010 Sep 1;26(17):2176-82
pubmed: 20610611
Cell Mol Immunol. 2021 May;18(5):1222-1234
pubmed: 33767434
Immunity. 2018 Apr 17;48(4):675-687.e7
pubmed: 29653696
Br J Cancer. 2018 Aug;119(4):440-449
pubmed: 30046165
Sci Transl Med. 2018 Jan 17;10(424):
pubmed: 29343622
J Hematol Oncol. 2019 Mar 12;12(1):27
pubmed: 30866992
J Hematol Oncol. 2019 Sep 14;12(1):98
pubmed: 31521196
J Hematol Oncol. 2020 Jul 16;13(1):96
pubmed: 32677994
Cancer Discov. 2021 Jun;11(6):1368-1397
pubmed: 33811048
Int Immunopharmacol. 2009 Jan;9(1):97-102
pubmed: 18992850
Acta Pharm Sin B. 2020 Dec;10(12):2272-2298
pubmed: 33354501
J Hematol Oncol. 2020 Jun 22;13(1):81
pubmed: 32571374
N Engl J Med. 2020 Oct 1;383(14):1328-1339
pubmed: 32997907
Exp Hematol Oncol. 2021 Mar 2;10(1):18
pubmed: 33653420
J Exp Clin Cancer Res. 2019 Aug 14;38(1):355
pubmed: 31412896
Exp Hematol Oncol. 2019 Feb 4;8:5
pubmed: 30740266
Oncoimmunology. 2018 May 24;7(8):e1466769
pubmed: 30221069
Nature. 2018 Feb 22;554(7693):538-543
pubmed: 29443964
Oncoimmunology. 2020 Sep 22;9(1):1824631
pubmed: 33457101
Cell. 2018 Oct 4;175(2):313-326
pubmed: 30290139
Annu Rev Nutr. 2015;35:71-108
pubmed: 25974698
Mol Cancer. 2019 Mar 30;18(1):60
pubmed: 30925919
J Hematol Oncol. 2019 Jan 14;12(1):7
pubmed: 30642373
Methods. 1999 Aug;18(4):459-64
pubmed: 10491275
Nat Rev Clin Oncol. 2016 Mar;13(3):143-58
pubmed: 26598942
J Immunol. 2013 May 15;190(10):5216-25
pubmed: 23585680
Mol Cancer. 2018 Aug 23;17(1):129
pubmed: 30139382
Exp Hematol Oncol. 2019 Aug 22;8:19
pubmed: 31463163
J Clin Invest. 2015 Sep;125(9):3384-91
pubmed: 26325035
J Hematol Oncol. 2020 May 24;13(1):58
pubmed: 32448366
Mol Cancer. 2019 Nov 6;18(1):155
pubmed: 31690319
Exp Hematol Oncol. 2020 Aug 3;9:17
pubmed: 32775040
Immunity. 2019 Apr 16;50(4):924-940
pubmed: 30995507
Neurotoxicology. 1999 Apr-Jun;20(2-3):161-71
pubmed: 10385880
Cancer Immunol Res. 2019 Apr;7(4):630-643
pubmed: 30755403
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
J Hematol Oncol. 2021 Feb 16;14(1):27
pubmed: 33593403
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
J Hematol Oncol. 2020 Jun 29;13(1):83
pubmed: 32600443
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Exp Hematol Oncol. 2019 Oct 25;8:26
pubmed: 31673481
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Science. 2020 Aug 21;369(6506):
pubmed: 32820094
Adv Immunol. 2020;145:187-241
pubmed: 32081198
Exp Hematol Oncol. 2020 May 25;9:10
pubmed: 32509418
Int J Biochem Cell Biol. 2021 Jul;136:106002
pubmed: 33962022
Exp Hematol Oncol. 2018 Nov 16;7:28
pubmed: 30473928
Sci Transl Med. 2016 Mar 2;8(328):328rv4
pubmed: 26936508
Nat Rev Immunol. 2006 Oct;6(10):715-27
pubmed: 16977338
J Hematol Oncol. 2018 Apr 10;11(1):53
pubmed: 29636079
J Hematol Oncol. 2019 Apr 1;12(1):35
pubmed: 30935414
J Hematol Oncol. 2020 Aug 12;13(1):111
pubmed: 32787882
Front Immunol. 2019 Apr 12;10:774
pubmed: 31031765

Auteurs

Ming Yi (M)

Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, People's Republic of China.

Mengke Niu (M)

Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, People's Republic of China.

Jing Zhang (J)

Wuhan YZY Biopharma Co., Ltd, Biolake, C2-1, No.666 Gaoxin Road, Wuhan, 430075, People's Republic of China.

Shiyu Li (S)

Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, People's Republic of China.

Shuangli Zhu (S)

Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, People's Republic of China.

Yongxiang Yan (Y)

Wuhan YZY Biopharma Co., Ltd, Biolake, C2-1, No.666 Gaoxin Road, Wuhan, 430075, People's Republic of China.

Ning Li (N)

Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, People's Republic of China.

Pengfei Zhou (P)

Wuhan YZY Biopharma Co., Ltd, Biolake, C2-1, No.666 Gaoxin Road, Wuhan, 430075, People's Republic of China.

Qian Chu (Q)

Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, People's Republic of China.

Kongming Wu (K)

Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, People's Republic of China. wukm_lab@163.com.
Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, People's Republic of China. wukm_lab@163.com.
ORCID: 0000-0003-2499-1032

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Combine and conquer: manganese synergizing...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps bispécifiques › Combine and conquer: manganese synergizing...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › Combine and conquer: manganese synergizing...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Combine and conquer: manganese synergizing...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Interactions médicamenteuses › Synergie des médicaments › Combine and conquer: manganese synergizing...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Combine and conquer: manganese synergizing...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › Inhibiteurs de points de contrôle immunitaires › Combine and conquer: manganese synergizing...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › Combine and conquer: manganese synergizing...
questionsmedicales.fr › Produits chimiques inorganiques › Métaux › Métaux lourds › Manganèse › Combine and conquer: manganese synergizing...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée BALB C › Combine and conquer: manganese synergizing...
questionsmedicales.fr › Tumeurs › Combine and conquer: manganese synergizing...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Protéines de la superfamille du TGF bêta › Facteur de croissance transformant bêta › Combine and conquer: manganese synergizing...